QNCX
Quince Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$31.73
+8.07%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -45.3%
- EBIT
- —
- EPS
- +50.4%
- Free cash flow
- -29.5%
- Operating cash flow
- -31.0%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +57.1%
- EPS
- +92.4%
Three-year CAGR
- Revenue
- —
- EBITDA
- —
- EBIT
- +12.0%
- Net income
- -47.8%
- EPS
- -28.2%
- Free cash flow
- -29.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026